The presence of antibodies against an
|
|
- Beatrice Preston
- 5 years ago
- Views:
Transcription
1 Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Autoantibodies to a 38-kDa Glycosylated Islet Cell Membrane Associated Antigen in (Pre)type 1 Diabetes Association with IA-2 and islet cell autoantibodies FREDERIC WINNOCK, PHARM 1 MICHAEL R. CHRISTIE, PHD 2 MANOU R. BATSTRA, PHD 3 HENK-JAN AANSTOOT, MD, PHD 3 ILSE WEETS, MD 1 KATELIJN DECOCHEZ, MD 1 PHILIPPE JOPART, MD 4 DANY NICOLAIJ, MD 5 FRANS K. GORUS, MD, PHD 1 THE BELGIAN DIABETES REGISTRY 6 OBJECTIVE To study the association of autoantibodies against a 38-kDa glycated islet cell membrane associated (GLIMA) protein with (pre)type 1 diabetes, patient characteristics, and other immune and genetic markers of the disease and to evaluate the possible added value of GLIMA antibody determinations for disease prediction and classification. RESEARCH DESIGN AND METHODS Recent-onset type 1 diabetic patients (n 100), prediabetic siblings (n 23), and nondiabetic control subjects (n 100) were consecutively recruited by the Belgian Diabetes Registry. GLIMA antibodies were determined by immunoprecipitation of radiolabeled islet cell proteins; islet cell antibodies (ICAs) were determined by indirect immunofluorescence; and insulin autoantibodies (IAAs), insulinoma-associated protein-2 antibodies (IA-2As), and GAD antibodies (GADAs) were determined by radioligand assays. RESULTS GLIMA antibodies were detected in 38% of type 1 diabetic patients and 35% of prediabetic siblings (during follow-up) vs. 0% in control subjects (P 0.001). Their prevalence was lower than that of other antibodies and was significantly associated with high levels of IA-2A and ICA (P ). In (pre)diabetes, GLIMA antibodies could only be demonstrated in sera positive for 1 other autoantibody. CONCLUSIONS GLIMA antibodies are strongly associated with type 1 diabetes and antibody markers of rapid progression to clinical onset but have a lower diagnostic sensitivity for the disease than IAA, ICA, IA-2A, or GADA. In its present form, the GLIMA antibody assay does not provide much additional information for prediction or classification of diabetes, compared with that obtained from the measurement of IA-2As alone or in combination with IAAs, ICAs, and GADAs. Diabetes Care 24: , 2001 From the 1 Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium; the 2 Department of Diabetes, Endocrinology and Internal Medicine, Guy s, King s College and St. Thomas School of Medicine, London, U.K.; the 3 Department of Pediatrics, Sophia s Children s Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands; the 4 Department of Endocrinology, Hôpital de Jolimont, Haine-Saint- Paul; the 5 Department of Endocrinology, O.L.V. Hospitaal, Kortrijk; and 6 Brussels, Belgium. Address correspondence and reprint requests to F.K. Gorus, MD, PhD, Diabetes Research Center, Vrije University Brussel, Laarbeeklaan 103, B-1090, Brussels, Belgium. frans.gorus@az.vub.ac.be. Received for publication 19 January 2001 and accepted in revised form 30 March Abbreviations: GADA, GAD antibody; GLIMA, glycated islet cell membrane associated protein; IA-2, insulinoma-associated protein-2; IA-2A, IA-2 antibody; IAA, insulin autoantibody; ICA, islet cell antibody; JDF U, Juvenile Diabetes Foundation units; TX-114, Triton X-114. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. The presence of antibodies against an as yet unidentified 38-kDa glycated islet cell membrane associated (GLIMA) protein has been proposed as a new biological marker of preclinical and recent-onset type 1 diabetes (1,2). It remains an open question so far whether the detection of these autoantibodies provides extra information for prediction or classification of clinical diabetes in addition to that obtained from the presence and levels of established diabetesassociated antibody markers. These include islet cell autoantibodies (ICAs), insulin autoantibodies (IAAs), and antibodies against the 65-kDa isoform of GAD and insulinoma-associated protein-2 (IA-2), a protein tyrosine phosphatase with unknown function in the islet cells (3 5). Taking into account the striking age-dependent heterogeneity of type 1 diabetes in terms of incidence, male-tofemale ratio, clinical presentation, and biological markers (3), we have determined GLIMA antibodies in parallel with IAA, ICA, GAD antibodies (GADAs), and IA-2 antibodies (IA-2As) in representative groups of recent-onset type 1 diabetic patients, prediabetic siblings of type 1 patients, and nondiabetic control subjects (0 39 years). This was done with the purpose of 1) confirming the diabetesassociation of GLIMA antibodies, 2) assessing their possible association with demographic data (age and sex) and with established immune (IAA, ICA, GADA, and IA-2A) or genetic (HLA DQ and the 5 flanking region of insulin gene [5 INS]) markers of type 1 diabetes (6), and 3) investigating whether the determination of GLIMA antibodies may help refine disease prediction and classification. RESEARCH DESIGN AND METHODS Recent-onset type 1 diabetic patients (n 100, 0 7 days of insulin treatment) and prediabetic siblings DIABETES CARE, VOLUME 24, NUMBER 7, JULY
2 GLIMA antibodies in type 1 diabetes (n 23, 3 77 months before diagnosis) aged 0 39 years were consecutively recruited by the Belgian Diabetes Registry (3,7). Type 1 diabetes was diagnosed according to the criteria of the National Diabetes Data Group (8). Demographic and clinical data were obtained by a questionnaire completed by physicians participating in the Belgian Diabetes Registry. Nondiabetic control subjects (n 100) were recruited among blood donors and laboratory personnel (aged years) and among children or adolescents attending emergency departments of Brussels hospitals for minor local surgery (7). Blood sampling Blood was collected in K-EDTA tubes (Monovettes; Sarstedt, Essen, Belgium) for HLA-DQ and 5 INS genotyping and in dry Monovettes (Sarstedt) for all other analytes. In diabetic subjects, blood was sampled before the start or within 7 days of insulin treatment. Serum and K-EDTA blood were transferred to aliquots and stored frozen at 80 C until further analysis. Autoantibody assays All antibody assays were performed by operators blinded for the identification and glycemic status of the study subjects. For the GLIMA antibody assay, we prepared Triton X-114 (TX-114) extracts of a subculture of RIN 5AH cells that were shown to have undetectable levels of GAD (9) and IA-2 by immunoprecipitation and Western blotting. The cells were cultured in the presence of 35 S methionine (L- [ 35 S]-methionine; Amersham Pharmacia Biotech, Uppsala, Sweden) for 7hand harvested in HEPES-buffered saline containing protease inhibitors as previously described (9), and the cell pellet was stored frozen at 80 C until further processing. The cells were lysed in buffer containing 2% TX-114 for 2 h by repeated dispersion through a constricted pipette tip, followed by a 30-min centrifugation to remove insoluble material. Amphiphilic proteins were isolated by temperatureinduced TX-114 phase separation (10). For the immunoprecipitation, an equivalent of cpm of detergent-phase purified extract was incubated overnight with 5 l of serum in a total volume of 25 l. In blocking studies to investigate the possibility that epitopes for GLIMA antibodies are shared with IA-2, 5 g ofunlabelled recombinant IA-2 was added during the overnight incubation. Immune complexes were isolated using 5 l of protein A-Sepharose per sample. Immunoprecipitates were evaluated by SDS- PAGE using 10% polyacrylamide gels and autoradiography. A sample was considered positive if a typical GLIMA38 band (1,2) was visible within 3 months of exposure to the X-ray film. Fluctuations in immune reactivity were evaluated by a semiquantitative analysis on a densitometric scan of the precipitated GLIMA38 protein. The intensity of GLIMA bands was related to that of a positive control serum obtained from a patient with recent-onset type 1 diabetes and was expressed as a GLIMA index (1). ICAs were measured by indirect immunofluorescence using cryosections of human blood group O donor pancreata (11). IAAs, GADAs, and IA-2As were determined by liquid-phase radiobinding assays using, respectively, 125 I-labeled insulin, 35 S-labeled GAD65, and the 35 S- labeled intracellular domain of IA-2 (IA- 2ic) as tracer (12). The cutoff values for ICAs ( 12 Juvenile Diabetes Foundation units [JDF U]), IAAs ( 0.6% tracerbound), GADAs ( 2.6% tracer-bound), and IA-2As ( 0.4% tracer-bound) were established as the 99th percentile of 783 healthy control subjects after omission of outlying values (12). The IAA, ICA, IA- 2A, and GADA assays repeatedly achieved 100% diagnostic sensitivity, specificity, consistency, and validity in serum exchange programs of the University of Florida and the Louisiana State University. In the combinatorial islet antibody workshop, assay sensitivity that was adjusted for 99% specificity amounted to 73, 36, and 85% for ICA, IAA, and GADA, respectively (IA-2A assay was not yet performed in 1995) (13). HLA-DQ and 5 INS genotyping DNA-polymorphisms at the HLA-DQ gene and 5 flanking region of the insulin gene were determined as previously described (14). Statistical analysis Differences between groups were assessed by two-tailed 2 test with Yates correction or Fisher s exact test, when appropriate, for categorical variables and with Mann-Whitney U test for continuous variables. Differences were considered significant at P 0.05 or, in the case of k comparisons, at P 0.05/k Figure 1 Immunoprecipitation analysis of GLIMA antibodies in sera. Test sera from diabetic patients (1 13) and negative ( ) or positive ( ) control sera were analyzed for the ability to immunoprecipitate a 38,000-Mr (38k, arrow) protein from extracts of 35 S- methionine labeled RIN m5ah cells. The figure illustrates a typical autoradiogram from the analysis. The samples that tested positive (as determined by densitometry from the original gels) are lanes 3, 5 (weak), 8, 10, 12, and 13. (Bonferroni adjustment). Stepwise forward logistic regression was used for multivariate analysis. All statistical tests were performed by SPSS for Windows version 8.0 (SPSS, Chicago, IL) for personal computers. RESULTS Examples of immunoprecipitation patterns observed in GLIMA antibody positive and negative sera are shown in Fig. 1. GLIMA antibodies were detected in 38 of 100 recent-onset type 1 diabetic patients (38%) but in none of the 100 nondiabetic control subjects (0%) (P vs. control subjects). Positivity for GLIMA antibodies was also found in 6 of 23 (26%) prediabetic siblings at first sampling (P 0.001). Two more siblings became positive after initial sampling but before diabetes onset. Thus, GLIMA antibodies were observed at some point before diagnosis in 8 of 23 siblings (35%). In both patients and siblings at first sampling, GLIMA antibodies were less prevalent than GADAs (80 and 74%, respectively), ICAs (66 and 70%), IA-2As (60 and 61%), and IAAs (38 and 52%). The occurrence of GLIMA antibodies was not dependent on sex, GADA, IAA, or certain genetic markers (HLA-DQA1* 0501-DQB1* 0201 haplotype in patients and relatives; the 5 INS I/I risk genotype was only investigated in patients) (Table 1). At clinical onset, the prevalence of GLIMA antibodies tended to be higher in patients under the age of 15 years at diagnosis or in those carrying the HLA-DQA1* 0301-DQB1* 0302 risk haplotype (P 0.04) (Table 1). GLIMA antibodies were almost exclusively detected in IA-2A or 1182 DIABETES CARE, VOLUME 24, NUMBER 7, JULY 2001
3 Winnock and Associates Table 1 Prevalence of antibodies against GLIMA in recent-onset type 1 diabetic patients and prediabetic siblings at first sampling Characteristics ICA-positive patients (P vs. absence of IA-2A or ICA) or siblings (P 0.05 vs. absence of IA-2A) (Table 1). In patients, ICA and IA-2A levels were significantly higher in the presence of GLIMA antibodies than in their absence (P ) (Fig. 2). A similar nonsignificant tendency was noted in siblings (Fig. 2). When patients and prediabetic siblings were pooled, the difference in IA-2A and ICA levels according to GLIMA antibody status persisted (P ), even when the analysis was restricted to IA-2A positive or ICA-positive subjects (not shown). In both patients and siblings, GLIMA antibodies could not be detected in the combined absence of IAA, ICA, GADA, and IA-2A (Table 1). Taking into account sex, age, presence of antibodies (IAA, ICA, GADA, and Prevalence of GLIMA antibodies Type 1 diabetic patients Prediabetic siblings (first sample) All subjects 38/100 (38) 6/23 (26) Male 18/56 (32) 3/12 (25) Female 20/44 (46) 3/11 (27) Age (years) /39 (51) 3/15 (20) /61 (30)* 3/8 (38) ICA (JDF U) 12 37/66 (56) 6/16 (38) 12 1/34 (3) 0/7 (0) GADA (%) /80 (38) 5/17 (29) 2.6 8/20 (40) 1/6 (17) IA-2A (%) /60 (60) 6/14 (43) 0.4 2/40 (5) 0/9 (0) IAA (%) /38 (42) 3/12 (25) /62 (36) 3/11 (27) IAA and/or ICA and/or GADA and/or IA-2A 38/92 (41) 6/22 (27) No IAA, no ICA, no GADA, no IA-2A 0/8 (0) 0/1 (0) HLA-DQAI*-DQBI* /60 (47) 5/19 (26) Non( ) 10/40 (25) 1/4 (25) /53 (34) 3/15 (20) Non( ) 20/47 (43) 3/8 (38) 5 INS I/I 26/65 (40) not done Non (I/I) 11/32 (34) Data are n (%). Fisher s exact test: *P 0.04 vs. age 0 14 years, P vs. ICA 12 JDF U; P 0.001, and P 0.05 vs. IA-2A 0.4%; P 0.04 vs Threshold for significance: P 0.05/19 or P (Bonferroni correction for multiple comparisons). IA-2A), and HLA-DQA1* -DQB1* risk haplotypes ( or ), multivariate analysis confirmed the preferential association of GLIMA antibodies with IA-2As (P 0.002) and ICAs (P 0.01) in patients. Taking into consideration log-transformed levels of IAA, ICA, GADA, and IA-2A instead of antibody prevalence, multivariate analysis revealed only an association between GLIMA antibody positivity and IA-2A levels (P 0.001). Incubation of GLIMA antibody positive sera with 5 g recombinant human IA-2ic, conditions that effectively block antibody binding to IA-2 and in many sera IA-2 (15,16), failed to block antibody binding to GLIMA (Fig. 3) in the immunoprecipitation test, indicating that the association between antibodies to IA-2 and GLIMA is not the result of shared antigenic epitopes. GLIMA-positive and GLIMA-negative patients did not differ significantly in terms of age, prevalence of ketonuria, frequency or duration of typical clinical symptoms (polyuria, polydipsia, weight loss, and fatigue), random C-peptide levels, HbA 1c levels, and daily insulin dose (results not shown). We found that 8 of 23 prediabetic siblings (35%) became positive for GLIMA antibodies at some time during the preclinical phase (Table 2). In none of these subjects were GLIMA antibodies detected before the appearance of other autoantibody markers. One prediabetic sibling seroconverted to GLIMA antibody positivity before clinical onset, but that subject remained IA-2A negative (Table 2). The only prediabetic sibling found to be positive for ICAs but negative for the molecular autoantibodies (GADA, IA-2A, and IAA) remained negative for GLIMA antibodies (not shown). CONCLUSIONS Our results confirm that antibodies against a 38-kDa GLIMA protein mark the early phase of type 1 diabetes (1,2). In the present series of 100 patients and 23 prediabetic siblings consecutively recruited by the Belgian Diabetes Register, the prevalence of GLIMA antibodies was, respectively, 38 and 35% at some time point during follow-up, which is higher than the prevalences reported in previous publications (23% in patients, P by Fisher s exact test; 14% in first degree relatives, P 0.06) (1,2). The higher sensitivity in our study was not obtained at the expense of a lower specificity because none of the 100 age-matched control subjects tested positive. Furthermore, the present study documents in both patients and prediabetic siblings a striking association of GLIMA antibody positivity with the presence of IA-2A, a strong predictor of imminent clinical onset in prediabetes (17 19). Because the probability of progressing to clinical diabetes increases with ICA titer (20) and IA-2A levels (19) in first degree relatives, the association of these high antibody levels with GLIMA antibody positivity suggests that the appearance of this new marker signals future diabetes onset. Similar to IA-2A, GLIMA antibodies tended to be more frequent in patients with childhood-onset diabetes and in those carrying HLA-DQA1* DQB1* 0302 (18), but after adjustment for the presence of IA-2A, these associ- DIABETES CARE, VOLUME 24, NUMBER 7, JULY
4 GLIMA antibodies in type 1 diabetes Figure 2 Levels of IA-2A and ICA in recent-onset type 1 diabetic patients and in prediabetic siblings stratified according to the presence (Œ) or absence ( ) of GLIMA antibodies. The horizontal dotted line represents the cutoff for ICA positivity or IA2-A positivity, and the horizontal full line represents the median value for each subject group (P value by Mann-Whitney U test). ations disappeared in multivariate analysis. Despite the strong association between IA-2A and GLIMA antibodies, it appears that the 38-kDa GLIMA antigen is not structurally related to IA-2 because preincubation of GLIMA antibody positive sera with recombinant human IA-2ic fails to block positivity in the immunoprecipitation assay. Moreover, several sera showed discordant results for both IA-2A and GLIMA antibody positivity. Using available technology, the diagnostic sensitivity of GLIMA antibodies in (pre)diabetes is still lower than that for IAAs, ICAs, IA-2As, and GADAs. At variance with Roll et al. (2), we could not find examples of GLIMA antibodies appearing as first autoantibody during the prediabetic phase. In contrast to IA-2As and GADAs, which usually remain detectable for years after clinical onset (12), GLIMA antibodies were reported to disappear rapidly after diagnosis (1). Therefore, the time window during which GLIMA antibodies can be detected in (pre)diabetes may, on average, be shorter than the window for GADAs or IA-2As. In neither patients nor siblings could we detect one single sample with GLIMA antibody positivity in the combined absence of IAA, ICA, IA-2A, and GADA. The only ICA-positive but GADA- and IA-2A negative prediabetic subject we identified remained GLIMA antibody negative, indicating that GLIMA was not the islet antigen recognized by the patient s ICA (18) DIABETES CARE, VOLUME 24, NUMBER 7, JULY 2001
5 Winnock and Associates Figure 3 Lack of cross-reactivity of antibodies to GLIMA and IA-2. Sera from a patient negative (a) or positive (b) for antibodies to GLIMA were incubated with extracts of 35 S- methionine labeled RIN m5ah cells in the absence ( ) or presence ( ) of5 g of purified recombinant IA-2ic. The addition of IA-2ic failed to block antibody binding to the 38,000-Mr (38k, arrow) GLIMA. Finally, the 38-kDa autoantigen has not yet been identified and cloned. Hence, radiobinding assays using radioactively labeled recombinant human 38- kda antigen are not available at the present time, rendering the measurement of GLIMA antibodies tedious and, at present, less suitable for high-throughput screening than IA-2A or GADA assays. The elaboration of a sensitive molecular binding assay for GLIMA antibodies should greatly facilitate the study of their precise relationship to IA-2A and GADA, and it should allow to better define their diagnostic performance for disease classification and prediction. Further characterization of the GLIMA antigen by both peptide mapping and the study of glycation patterns will provide a basis for its subsequent purification and identification (2). In conclusion, the present data confirm the association of GLIMA antibodies with type 1 diabetes, but antibody prevalence was higher than that previously reported. They also document the strong association between GLIMA antibodies and high levels of IA-2As and ICAs, which are considered markers of rapid progression to clinical diabetes in risk groups. However, in its present form, the GLIMA antibody assay is less sensitive, less quantitative, and more time-consuming than the IA-2A assay, and thus it does not provide much additional information for the prediction or classification of diabetes compared with information obtained from the measurement of IA-2As alone or Table 2 Levels of diabetes associated antibodies in serum samples of siblings who tested GLIMA antibody positive on at least one occasion during the preclinical phase of type 1 diabetes Sibling no. Sex Age (years) Months before diagnosis GLIMA antibodies ICA (JDF U) Autoantibodies GADA (%) IA-2A (%) 1 female male female , male male female male female , Results above the cutoff value for antibody positivity are indicated in bold. IAA (%) in combination with IAAs, ICAs, and/or GADAs. Acknowledgments This study was supported by the Belgian National Fund for Scientific Research (FWO Grants , , and ; Levenslijn ; and research fellowships to F.W. and K.D.), the Dutch Diabetes Foundation (DFN H in support of M.R.B. and grant DFN to H.J.A.), and Zorgonderzoek Nederland ( ). The Belgian Diabetes Registry is supported financially by the Ministries of Public Health of the French and Flemish Communities of Belgium, as well as Novo Nordisk, Life Scan, Boehringer Mannheim, Ortho Clinical Diagnosis, and Weight Watchers. We are indebted to Prof. Dr. D. Pipeleers (Diabetes Research Center, Brussels, Belgium) for critical reading and for generous support and to N. Alaerts, V. Baetens, M. Bodson, A. Demarré, L. De Pree, T. Demesmaeker, S. Exterbille, T. Ghysels, P. Goubert, C. Groven, A. Ivens, D. Kesler, F. Lebleu, E. Quartier, R. Raalgeep, and G. Schoonjans for excellent technical assistance. The following members of the Belgian Diabetes Registry have contributed to this study: P. Arnouts, J. Beirinckx, L. Claeys, M. Coeckelberghs, J-L. Coolens, W. Coucke, E. Couturier, R. Craen, J-C. Daubresse, P. Decraene, I. De Feyter, I. De Leeuw, J. De Schepper, H. Dorchy, M. Du Caju, L. Emsens, F. Féry, N. Gaham, K. Garmijn, J. Gérard, C. Gillet, J. Guiot, C. Herbaut, B. Keymeulen, G. Krzentowski, C. Mathieu, D. Rocour-Brumioul, R. Rottiers, A. Scheen, J. Schutyser, O. Segers, J. Teuwen, G. Thenaers, J. Tits, K. Van Acker, P. Van Crombrugge, E. Vandenbussche, D. Van Doorn, L. Van Gaal, S. Van Imschoot, S. Vanneste, and C. Vercammen. References 1. Aanstoot HJ, Kang SM, Kim J, Lindsay LA, Roll U, Knip M, Atkinson M, Mose-Larsen P, Fey S, Ludvigsson J, Landin M, Bruining J, Maclaren N, Åkerblom HK, Baekkeskov S: Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA-2 marks the early phases of autoimmune response in type 1 diabetes. J Clin Invest 97: , Roll U, Turck CW, Gitelman SE, Rosenthal SM, Nolte MS, Masharani U, Ziegler AG, Baekkeskov S: Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in type I diabetic patients. Diabetologia 43: , Gorus FK, the Belgian Diabetes Registry: Diabetes registries and early biological markers of insulin-dependent diabetes DIABETES CARE, VOLUME 24, NUMBER 7, JULY
6 GLIMA antibodies in type 1 diabetes mellitus. Diabete Metab Rev 13: , Slover RH, Eisenbarth GS: Prevention of type I diabetes and recurrent beta-cell destruction of transplanted islets. Endocr Rev 18: , Bingley PJ, Bonifacio E, Gale EA: Can we really predict IDDM? (Review) Diabetes 42: , Todd JA: Genetic analysis of type 1 diabetes using whole genome approaches. Proc Natl Acad Sci U S A92: , Vandewalle CL, Coeckelberghs MI, De Leeuw IH, Du Caju MV, Schuit FC, Pipeleers DG, Gorus FK, the Belgian Diabetes Registry: Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years: comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. Diabetes Care 20: , National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: , Christie MR, Hollands JA, Brown TJ, Michelsen BK, Delovitch TL: Detection of pancreatic islet 64,000 Mr autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J Clin Invest 92: , Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, DeCamilli P: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABAsynthesizing enzyme glutamic acid decarboxylase. Nature 347: , Vandewalle CL, Decraene T, Schuit FC, De Leeuw IH, Pipeleers DG, Gorus FK, the Belgian Diabetes Registry: Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical onset of type 1 (insulindependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. Diabetologia 36: , Decochez K, Tits J, Coolens J-L, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK, the Belgian Diabetes Registry: High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. Diabetes Care 23: , Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS: Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47: , Van der Auwera B, Schuit F, Lyaruu I, Falorni A, Svanholm S, Vandewalle CL, Gorus FK, the Belgian Diabetes Registry: Genetic susceptibility for insulin-dependent diabetes mellitus in Caucasians revisited: the importance of diabetes registries in disclosing interactions between HLA-DQ- and insulin gene-linked risk. J Clin Endocrinol Metab 80: , Payton MA, Hawkes CJ, Christie MR: Relationship of the 37,000- and 40,000-Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96: , Hatfield ECI, Hawkes CJ, Payton MA, Christie MR: Cross reactivity between IA-2 and phogrin/ia-2 in binding of autoantibodies in IDDM. Diabetologia 40: , Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/ IA-2 autoantibodies. Diabetes 45: , Gorus FK, Goubert P, Semakula C, Vandewalle CL, De Schepper J, Scheen A, Christie MR, Pipeleers DG, the Belgian Diabetes Registry: IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 40:95 99, Kulmala P, Savola K, Petersen JS, Vahasalo P, Karjalainen J, Lopponen T, Dyrberg T, Åkerblom HK, Knip M: Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes: a population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 101:327 36, Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, Gale EA, Bottazzo GF: Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 335: , DIABETES CARE, VOLUME 24, NUMBER 7, JULY 2001
IA-2-autoantibodies complement GAD 65 -autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings
Diabetologia (1997) 40: 95 99 Springer-Verlag 1997 Rapid communications IA-2-autoantibodies complement GAD 65 -autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings
More informationType 1A diabetes is strongly associated with the
Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA Relatives Is Associated With Eligibility for the Diabetes Prevention Trial Type 1 Liping Yu, 1 David D. Cuthbertson,
More information/02/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 87(6): Copyright 2002 by The Endocrine Society
0013-7227/02/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 87(6):2597 2605 Printed in U.S.A. Copyright 2002 by The Endocrine Society Relation between Disease Phenotype and HLA-DQ Genotype
More informationARTICLE. Diabetologia (2012) 55: DOI /s
Diabetologia (2012) 55:413 420 DOI 10.1007/s00125-011-2376-1 ARTICLE An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody
More informationRelation between Disease Phenotype and HLA-DQ Genotype in Diabetic Patients Diagnosed in Early Adulthood
Relation between Disease Phenotype and HLA-DQ Genotype in Diabetic Patients Diagnosed in Early Adulthood ILSE WEETS 1, VALERIE SIRAUX 2, JEAN-CLAUDE DAUBRESSE 3, IVO H. DE LEEUW 5, FRANÇOISE FÉRY 2, BART
More informationb-cell Autoantibodies and Their Function in Taiwanese Children With Type 1 Diabetes Mellitus
ORIGINAL ARTICLE b-cell Autoantibodies and Their Function in Taiwanese Children With Type 1 Diabetes Mellitus Yi-Ching Tung, 1 Mei-Huei Chen, 2 Cheng-Ting Lee, 1 Wen-Yu Tsai 1 * Background/Purpose: To
More informationComplete Diabetes Mellitus Panel, Brochure
Complete Diabetes Mellitus Panel, Brochure Interest in any of the products, request or order them at Bio-Connect Diagnostics. Bio-Connect Diagnostics B.V. T NL +31 (0)26 326 44 60 T BE +32 (0)2 502 12
More informationArticles. Abstract. Keywords Age Climate Environmental factors Epidemiology HLA-DQ Incidence Seasonality Sex Type 1 diabetes Viral infections
Diabetologia (2004) 47:614 621 DOI 10.1007/s00125-004-1369-8 Articles Seasonality in clinical onset of Type 1 diabetes in Belgian patients above the age of 10 is restricted to HLA-DQ2/DQ8-negative males,
More informationHyperglycaemic clamp test for diabetes risk assessment in IA-2-antibodypositive relatives of type 1 diabetic patients
Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibodypositive relatives of type 1 diabetic patients E. Vandemeulebroucke a B. Keymeulen a K. Decochez a I. Weets a C. De Block b F. Féry
More informationGAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy
Diabetologia (1996) 39: 1329 1333 Springer-Verlag 1996 GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy J.S. Petersen 1, T. Dyrberg 2, P.
More informationPart XI Type 1 Diabetes
Part XI Type 1 Diabetes Introduction Åke Lernmark Epidemiology Type 1 diabetes is increasing worldwide and shows epidemic proportions in several countries or regions [1]. There is evidence to suggest that
More informationValidity of Screening for Individuals at Risk for Type I Diabetes by Combined Analysis ot Antibodies to Recombinant Proteins
E p i d e m i o I o g y H e a h S e r v i c e s P s y c h o s o c i a I N A L A R T I C L E Research Validity of Screening for Individuals at Risk for Type I Diabetes by Combined Analysis ot Antibodies
More informationAbstract. Keywords Type 1 diabetes, HLA-DQB1, Autoantibody, Finland, General population, Risk group.
Diabetologia (2003) 46:65 70 DOI 10.1007/s00125-002-0976-5 Signs of beta-cell autoimmunity and HLA-defined diabetes susceptibility in the Finnish population: the sib cohort from the Type 1 Diabetes Prediction
More informationIntroduction ARTICLE. Carolyn C. Richardson 1,2 & Kerry A. McLaughlin 1 & Diana Morgan 3 & Richard G. Feltbower 3 & Michael R.
Diabetologia (2016) 59:334 340 DOI 10.1007/s00125-015-3803-5 ARTICLE Influence of HLA-DR and -DQ alleles on autoantibody recognition of distinct epitopes within the juxtamembrane domain of the IA-2 autoantigen
More informationDiabetes Care 33: , 2010
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Prediction of Type 1 Diabetes in the General Population MIKAEL KNIP, MD, PHD 1,2,3 SARI KORHONEN, MD 4 PETRI KULMALA, MD, PHD 4 RIITTA
More informationDiabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2
Diabetologia (2008) 51:846 852 DOI 10.7/s00125-008-0967-2 ARTICLE Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2 C.
More informationGAD65 Autoantibodies Detected by Electrochemiluminescence Assay Identify High Risk for Type 1 Diabetes
BRIEF REPORT GAD65 Autoantibodies Detected by Electrochemiluminescence Assay Identify High Risk for Type 1 Diabetes Dongmei Miao, K. Michelle Guyer, Fran Dong, Ling Jiang, Andrea K. Steck, Marian Rewers,
More informationDOI: /j x. Published: Link to publication
Islet antibodies and remaining beta-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden. Schölin, A.; Björklund,
More informationDiabetologia 9 Springer-Verlag 1992
Diabetologia (1992) 35:570-576 Diabetologia 9 Springer-Verlag 1992 Glutamic acid decarboxylase (GAD) autoantibodies are additional predictive markers of Type 1 (insulin-dependent) diabetes mellitus in
More informationAutoimmune diagnostics in diabetes mellitus 1)
Clin Chem Lab Med 2006;44(2):133 137 2006 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2006.025 2006/35 Review Autoimmune diagnostics in diabetes mellitus 1) Jochen Seissler* and Werner A. Scherbaum
More informationGAD65 autoantibody responses in Japanese latent autoimmune diabetes in adults (LADA) patients.
Diabetes Care Publish Ahead of Print, published online May 16, 2008 GAD65Ab epitope specificity distinguishes LADA GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adults (LADA) patients.
More informationLundgren, Markus; Lynch, Kristian; Larsson, Christer; Elding Larsson, Helena; Diabetes Prediction in Skåne study group; Carlsson, Annelie
Cord blood insulinoma-associated protein 2 autoantibodies are associated with increased risk of type 1 diabetes in the population-based Diabetes Prediction in Skane study Lundgren, Markus; Lynch, Kristian;
More informationX/00/$03.00/0 Vol. 85, No. 12 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 12 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Prognostic Factors for the Course of Cell Function in
More informationARTICLE. Keywords HLA-DQB1 genotypes. Classification. C-peptide. Islet antibodies
Diabetologia (2006) 49: 1785 1794 DOI 10.1007/s00125-006-0293-5 ARTICLE E. Bakhtadze. H. Borg. G. Stenström. P. Fernlund. H. J. Arnqvist. A. Ekbom-Schnell. J. Bolinder. J. W. Eriksson. S. Gudbjörnsdottir.
More informationA Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial Type 1
Pathophysiology/Complications O R I G I N A L A R T I C L E A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial Type 1 JAY M. SOSENKO, MD 1
More informationPrognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population Receiver operating
More informationDiabetologia 9 Springer-Verlag 1992
Diabetologia (1992) 35:550-554 Diabetologia 9 Springer-Verlag 1992 Antibodies to the Mr 64,000 (64 K) protein in islet cell antibody positive non-diabetic individuals indicate high risk for impaired Beta-cell
More informationIslet Cell Autoantibodies in Cord Blood from Children with Blood Group Incompatibility or Hyperbilirubinemia
Autoimmunity, 2003 Vol. 36 (2), pp. 111 115 Islet Cell Autoantibodies in Cord Blood from Children with Blood Group Incompatibility or Hyperbilirubinemia A. MARIA ELFVING a, BENGT A. LINDBERG b, *, M. LANDIN-OLSSON
More informationM. Kukko, T. Kimpimäki, S. Korhonen, A. Kupila, S. Simell, R. Veijola, T. Simell, J. Ilonen, O. Simell, and M. Knip
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(5):2712 2717 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-1371 Dynamics of Diabetes-Associated
More informationARTICLE. Diabetologia (2007) 50: DOI /s
Diabetologia (27) 5:252 26 DOI 1.17/s125-7-745-6 ARTICLE GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression:
More informationComparison of the prevalence of islet autoantibodies according to age and disease duration in patients with type 1 diabetes mellitus
Original article http://dx.doi.org/10.6065/apem.2013.18.2.65 Ann Pediatr Endocrinol Metab 2013;18:65-70 Comparison of the prevalence of islet autoantibodies according to age and disease duration in patients
More informationEarly expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes
Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes Liping Yu, David T. Robles, Norio Abiru, Paramjit Kaur, Marian Rewers,
More informationPatients: Adult KPD patients (n 384) were followed longitudinally in a research clinic.
JCEM ONLINE Brief Report Endocrine Research Masked and Overt Autoantibodies Specific to the DPD Epitope of 65-kDa Glutamate Decarboxylase (GAD65- DPD) Are Associated With Preserved -Cell Functional Reserve
More informationDelay of Type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial
Diabetologia (1998) 41: 536±541 Ó Springer-Verlag 1998 Delay of Type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial
More informationClinical and Laboratory Characteristics of Childhood Diabetes Mellitus: A Single-Center Study from 2000 to 2013
Original Article www.cmj.ac.kr Clinical and Laboratory Characteristics of Childhood Diabetes Mellitus: A Single-Center Study from 2000 to 2013 Tae Hyun Park 1, Min Sun Kim 1,2, * and Dae-Yeol Lee 1,2 1
More informationAutoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes
Diabetologia (1999) 42: 3±14 Ó Springer-Verlag 1999 Review Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes R.D.G. Leslie 1, M. A. Atkinson 2, A.L. Notkins 3 1 Department of Diabetes and
More informationReversion of b-cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study DOI: /dc
Diabetes Care 1 Reversion of b-cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study DOI: 10.2337/dc16-0181 Kendra Vehik, 1 Kristian F. Lynch, 1 Desmond A. Schatz, 2 Beena Akolkar, 3 William Hagopian,
More informationLongitudinal Study for Prediction of Type 1 Diabetes in Siblings of Patients. An Initial Step for Prevention of Disease
Longitudinal Study for Prediction of Type 1 Diabetes in Siblings of Patients. An Initial Step for Prevention of Disease Shereen Abdel Ghaffar, Mona H. Hafez, Fatma A. El-Mogi, 1 Asmaa Elsherei, Nermeen
More informationin Insulin-dependent Diabetes Distinct from Glutamate Decarboxylase
Detection of Pancreatic Islet 64,000 Mr Autoantigens in Insulin-dependent Diabetes Distinct from Glutamate Decarboxylase Michael R. Christie,* Jaqueline A. Hollands, * Thomas J. Brown,* Birgitte K. Michelsen,6
More informationTHE HUMAN LEUKOCYTE antigen (HLA) haplotype
0021-972X/00/$03.00/0 Vol. 85, No. 3 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Islet Cell Antibody-Positive Relatives with Human Leukocyte
More informationIDDM1 and Multiple Family History of Type 1 Diabetes Combine to Identify Neonates at High Risk for Type 1 Diabetes
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E IDDM1 and Multiple Family History of Type 1 Diabetes Combine to Identify Neonates at High Risk for Type 1 Diabetes
More informationInstructions for Use. IA-2 Antibody RIA. for the Quantitative Determination of Antibodies against Protein-Tyrosine-Phosphatase (IA2) in Serum
Instructions for Use IA-2 Antibody RIA 125I-Radioimmunoassay for the Quantitative Determination of Antibodies against Protein-Tyrosine-Phosphatase (IA2) in Serum REF RA101/50 RA104/100 50 100 2 8 C I V
More informationElimination of Dietary Gluten Does Not Reduce Titers of Type 1 Diabetes Associated Autoantibodies in High-Risk Subjects
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Elimination of Dietary Gluten Does Not Reduce Titers of Type 1 Diabetes Associated Autoantibodies in High-Risk Subjects MICHAEL HUMMEL, MD
More informationDiabetologia 9 Springer-Verlag 1995
Diabetologia (15) 38:351-355 Diabetologia Springer-Verlag 15 Autoantibodies to the islet antigen ICA 6 occur in IDDM and in rheumatoid arthritis S. Martin 1, J. Kardorf 1, B. Schulte 1, E. F. Lampeter
More informationDiabetic Subjects Diagnosed Through the Diabetes Prevention Trial Type 1 (DPT-1) Are Often Asymptomatic With Normal A1C at Diabetes Onset
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Diabetic Subjects Diagnosed Through the Diabetes Prevention Trial Type 1 (DPT-1) Are Often Asymptomatic With Normal
More informationPreexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual b-cell Function in Recent-Onset Type 1 Diabetes
Diabetes Care 1 Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual b-cell Function in Recent-Onset Type 1 Diabetes Simke Demeester, 1 Bart Keymeulen, 1 Leonard Kaufman,
More informationAbstract. Introduction
Identification and Characterization of Glima 38, a Glycosylated Islet Cell Membrane Antigen, Which Together with GAD 65 and IA2 Marks the Early Phases of Autoimmune Response in Type 1 Diabetes Henk-Jan
More informationEarly Onset of Diabetes in the Proband Is the Major Determinant of Risk in HLA. DR3-DQ2/DR4-DQ8 siblings, the
Diabetes Volume 63, March 2014 1041 Kathleen M. Gillespie, Rachel J. Aitken, Isabel Wilson, Alistair J.K. Williams, and Polly J. Bingley Early Onset of Diabetes in the Proband Is the Major Determinant
More informationPrediction and Prevention of Type 1 Diabetes. How far to go?
Prediction and Prevention of Type 1 Diabetes. How far to go? Peter Colman Diabetes and Endocrinology Royal Melbourne Hospital Royal Melbourne Hospital Lancet, Saturday 30 th November 1974; p. 1279-1282
More informationIn pre type 1 diabetes, accurate timing of the appearance
Genetic Risk Determines the Emergence of Diabetes-Associated Autoantibodies in Young Children Antti Kupila, 1 Päivi Keskinen, 4 Tuula Simell, 1 Satu Erkkilä, 1 Paula Arvilommi, 1 Sari Korhonen, 3 Teija
More informationA New Luminescence Assay for Autoantibodies to Mammalian Cell-Prepared IA-2
Diabetes Care Publish Ahead of Print, published online June 5, 2008 New Luminescence Assay for Autoantibodies to IA-2 A New Luminescence Assay for Autoantibodies to Mammalian Cell-Prepared IA-2 Peter D.
More informationRole of Insulin Resistance in Predicting Progression to Type 1 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Role of Insulin Resistance in Predicting Progression to Type 1 Diabetes PING XU, MPH 1 DAVID CUTHBERTSON, MS 1 CARLA GREENBAUM, MD 2 JERRY P.
More informationDiabetologia 9 Springer-Verlag 1994
Diabetologia (1994) 37:365-371 Diabetologia 9 Springer-Verlag 1994 Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease R. Wagner
More informationE K. Gorus ~, J.-C.Sodoyez 2, D.G. Pipeleers 1, B. Keymeulen 1, A.Foriers 1, C.EH.Van Schravendijk 1 and the Belgian Diabetes Registry 3
Diabetologia (1992) 35:18-186 D",aDew " " ' og i a Springer-Verlag 1992 Detection of autoantibodies against islet amyloid polypeptide in human serum. Lack of association with Type 1 (insulin-dependent)
More informationHLA Genes, Islet Autoantibodies and Residual C-Peptide at the Clinical Onset of Type 1 Diabetes Mellitus and the Risk of Retinopathy 15 Years Later
HLA Genes, Islet Autoantibodies and Residual C-Peptide at the Clinical Onset of Type 1 Diabetes Mellitus and the Risk of Retinopathy 15 Years Later Jensen, Richard A.; Agardh, Elisabet; Lernmark, Åke;
More informationType 1 diabetes is an immune-mediated disease
ORIGINAL ARTICLE redictive Characteristics of Diabetes-Associated Autoantibodies Among Children With HLA-Conferred Disease Susceptibility in the General opulation Heli T.A. Siljander, 1,2 Satu Simell,
More informationChapter 10. Humoral Autoimmunity 6/20/2012
Chapter 10 Humoral Autoimmunity 6/20/2012 DIPP Populations Study: Quartile Levels Insulin Autoantibodies (6 month post first IAA) and progression to Diabetes Parrika et al Diabetologia 2012 MSD ELECTROCHEMILUMINESCENT
More information1. PATHOPHYSIOLOGY OF DIABETES MELLITUS
1. PATHOPHYSIOLOGY OF DIABETES MELLITUS Prof. Vladimir Palicka, M.D., Ph.D. Institute for Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic Diabetes mellitus is
More informationClass II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies
https://helda.helsinki.fi Class II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies Koskinen, Maarit K. 2018-08 Koskinen, M K, Lempainen, J, Löyttyniemi,
More informationProbiotics for the Prevention of Beta Cell Autoimmunity in Children at Genetic Risk of Type 1 Diabetes the PRODIA Study
Probiotics for the Prevention of Beta Cell Autoimmunity in Children at Genetic Risk of Type 1 Diabetes the PRODIA Study MARTIN LJUNGBERG, a RIITA KORPELA, b JORMA ILONEN, c JOHNNY LUDVIGSSON, a AND OUTI
More informationARTICLE. V. Parikka & K. Näntö-Salonen & M. Saarinen & T. Simell & J. Ilonen & H. Hyöty & R. Veijola & M. Knip & O. Simell
Diabetologia (212) 55:1926 1936 DOI 1.17/s125-12-2523-3 ARTICLE Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children
More informationDynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes
Diabetologia (25) 48: 922 93 DOI 1.7/s125-5-1719-1 ARTICLE M. Schlosser. J. P. Banga. A. M. Madec. K. A. Binder. M. Strebelow. I. Rjasanowski. R. Wassmuth. L. K. Gilliam. D. Luo. C. S. Hampe Dynamic changes
More informationEvgenija Homšak,M.Ph., M.Sc., EuSpLM. Department for laboratory diagnostics University Clinical Centre Maribor Slovenia
Evgenija Homšak,M.Ph., M.Sc., EuSpLM. Department for laboratory diagnostics University Clinical Centre Maribor Slovenia 14th EFLM Continuing Postgraduate Course in Clinical Chemistry and Laboratory Medicine
More informationLUP. Lund University Publications Institutional Repository of Lund University
LUP Lund University Publications Institutional Repository of Lund University This is an author produced version of a paper published in Diabetologia. This paper has been peer-reviewed but does not include
More informationA Study on the Presence of Islets Cell Autoantibodies in Non- Insulin Requiring Young Diabetic Patients
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 12 Ver. VI (Dec. 2015), PP 119-123 www.iosrjournals.org A Study on the Presence of Islets Cell
More informationDo stressful life events cause type 1 diabetes?
Occupational Medicine 2004;54:250 254 DOI: 10.1093/occmed/kqh047 Do stressful life events cause type 1? Martin Cosgrove Introduction Background The link between psychological stresses and deteriorating
More informationIslet autoimmunity leading to type 1 diabetes develops
CLINICAL RESEARCH ARTICLE Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives Emanuele Bosi, 1 David C. Boulware, 2 Dorothy J. Becker, 3 Jane
More informationEpitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes
Diabetologia (2000) 43: 210±217 Ó Springer-Verlag 2000 Epitope spreading and a varying but not disease-specific GAD65 antibody response in Type I diabetes P. Söhnlein 1, M.Müller 2, K. Syren 2, U. Hartmann
More informationCitation for published version (APA): Nilsson, C. (2013). Gestational Diabetes Mellitus- Future risk for mother and child Medicine (Lund)
Gestational Diabetes Mellitus- Future risk for mother and child Nilsson, Charlotta Published: 2013-01-01 Link to publication Citation for published version (APA): Nilsson, C. (2013). Gestational Diabetes
More informationAutoantibodies in Diabetes
Autoantibodies in Diabetes Catherine Pihoker, Lisa K. Gilliam, Christiane S. Hampe, and Åke Lernmark Islet cell autoantibodies are strongly associated with the development of type 1 diabetes. The appearance
More informationBiochemical markers could predict type-1 diabetes mellitus
Molecular and Biochemical Diagnosis (MBD) Vol 2, No 1, 2016 Original Article Biochemical markers could predict type-1 diabetes mellitus Ragaa H. M. Salama 1*, Yasser F. Abd-Elraheem 2, Khaled H. Mahmoud
More informationGlucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial Type 1
Pathophysiology/Complications O R I G I N A L A R T I C L E Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial Type 1 JAY M. SOSENKO, MD 1 JERRY P.
More informationShort communication. Abstract
Diabetologia (1999) 42: 574±578 Short communication Ó Springer-Verlag 1999 Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset
More informationIs It Time to Screen the General Population for Type 1 Diabetes?
Is It Time to Screen the General Population for Type 1 Diabetes? Kimber M Simmons, MD, MS 1 and Aaron W Michels, MD 2 1. Pediatric Endocrinology and Diabetes Fellow, Children s Hospital Colorado, Aurora,
More informationDiabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated pathologically with specific microvascular and macrovascular complications.
More informationGraves Hyperthyroidism after Stopping Immune Suppressive Therapy in Type 1 Diabetic Islet Cell Recipients with Pretransplant TPO-Autoantibodies
Diabetes Care Publish Ahead of Print, published online June 23, 2009 Graves Hyperthyroidism after Islet Transplantation Graves Hyperthyroidism after Stopping Immune Suppressive Therapy in Type 1 Diabetic
More informationAnti-islet autoantibodies in Japanese type 1 diabetes
15 th Korea Japan Symposium on Diabetes Anti-islet autoantibodies in Japanese type 1 diabetes Eiji Kawasaki, Katsumi Eguchi Nagasaki University Hospital, Nagasaki, Japan November 20 21, 21 2009 Cheju Islend
More informationNo Major Association of Breast-Feeding, Vaccinations, and Childhood Viral Diseases With Early Islet Autoimmunity in the German BABYDIAB Study
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E No Major Association of Breast-Feeding, Vaccinations, and Childhood Viral Diseases With Early Islet Autoimmunity in the
More informationType 1 diabetes is a genetically associated autoimmune
T-Cell Lines Reactive to an Immunodominant Epitope of the Tyrosine Phosphatase-Like Autoantigen IA-2 in Type 1 Diabetes Charlotte J. Hawkes, Nanette C. Schloot, Joanne Marks, Sabine J.M. Willemen, Jan
More informationThis information is current as of February 23, 2013.
This information is current as of February 23, 2013. References Subscriptions Permissions Email Alerts Two Distinctly HLA-Associated Contiguous Linear Epitopes Uniquely Expressed Within the Islet Antigen
More informationArticles. Abstract. Keywords Autoantibodies, BMI, C-peptide, classification, GADA, IA-2, ICA, idiopathic, Type 1 diabetes, Type 2 diabetes.
Diabetologia (2003) 46:173 181 DOI 10.1007/s00125-002-1021-4 Articles Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15 34 yrs) in the Diabetes
More informationoriginal article INTRODUCTION Autoimmune thyroid diseases (ATDs), represented ABSTRACT
original article Prevalence of pancreatic autoantibodies in non-diabetic patients with autoimmune thyroid disease and its relation to insulin secretion and glucose tolerance Carolina Sallorenzo 1, Regina
More informationORIGINAL CONTRIBUTIONS. Antibodies to Glutamic Acid Decarboxylase and Diabetes Mellitus in the Multiple Risk Factor Intervention Trial
American Journal of Epidemiology Vol. 140, No. 8 Copyright 1994 by The Johns Hopkins University School of Hygiene and Public Health Printed in U.S.A. All rights reserved ORIGINAL CONTRIBUTIONS Antibodies
More informationJEFFREY P. KRISCHER, PHD 1 JAY M. SOSENKO, MD 4 JAY S. SKYLER, MD 4 ON BEHALF OF THE DIABETES PREVENTION TRIAL TYPE 1 (DPT-1) STUDY GROUP
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes PING XU, MPH 1 YOUGUI WU, PHD 2
More informationAutoimmune diabetes is characterized by the
ORIGINAL ARTICLE Identification of Tyrosine Phosphatase 2 (256 760) Construct as a New, Sensitive Marker for the Detection of Islet Autoimmunity in Type 2 Diabetic Patients The Non Insulin Requiring Autoimmune
More informationIdentification of Autoantibody-Negative Autoimmune Type 2 Diabetic Patients 6,7
Pathophysiology/Complications O R I G I N A L A R T I C L E Identification of Autoantibody-Negative Autoimmune Type 2 Diabetic Patients BARBARA M. BROOKS-WORRELL, PHD 1,2,3,4 JESSICA L. REICHOW, BS 3 AMIT
More informationDiabetes Care Publish Ahead of Print, published online June 14, 2010
Diabetes Care Publish Ahead of Print, published online June 14, 2010 Polyendocrinopathy in children, adolescents and young adults with type 1 diabetes. A multicenter analysis of 28,671 patients from the
More informationRELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES. Yuan Gu
RELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES by Yuan Gu BE, Nanjing Institute of Technology, China, 2006 ME, University of Shanghai for
More informationAutoantibodies against islet cell antigens are. Diabetes Antibody Standardization Program: First Assay Proficiency Evaluation
Diabetes Antibody Standardization Program: First Assay Proficiency Evaluation Polly J. Bingley, 1 Ezio Bonifacio, 2 Patricia W. Mueller, 3 and Participating Laboratories The aims of the first proficiency
More informationLADA prevalence estimation and insulin dependency during follow-up
DIABETES/METABOLISM RESEARCH AND REVIEWS Diabetes Metab Res Rev 2011; 27: 975 979. Published online in Wiley Online Library (wileyonlinelibrary.com).1278 RESEARCH ARTICLE LADA prevalence estimation and
More informationTime dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway
Diabetologia (2012) 55:1310 1318 DOI 10.1007/s00125-012-2463-y ARTICLE Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT
More informationLatent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity
Online Submissions: http://www.wjgnet.com/1948-9358office wjd@wjgnet.com doi:10.4239/wjd.v1.i4.111 World J Diabetes 2010 September 15; 1(4): 111-115 ISSN 1948-9358 (online) 2010 Baishideng. All rights
More information2 Screen Islet Cell Autoantibody Human ELISA
2 Screen Islet Cell Autoantibody Human ELISA Cat. No.:DEIA4453 Pkg.Size:96T Intended use The 2 Screen Islet Cell autoantibody (2 Screen) ELISA kit is intended for use by professional persons only, for
More informationLatent autoimmune diabetes in adults: a guide for the perplexed
Diabetologia (2005) 48: 2195 2199 DOI 10.1007/s00125-005-1954-5 EDITORIAL E. A. M. Gale Latent autoimmune diabetes in adults: a guide for the perplexed Published online: 29 September 2005 # Springer-Verlag
More informationIPS Modern management of childhood diabetes mellitus
Modern management of childhood diabetes mellitus Professor Philippe LYSY, MD PhD Pediatric endocrinology and diabetology Institut de Recherche Expérimentale et Clinique Université Catholique de Louvain
More informationASSESSMENT OF THE RISK FOR TYPE 1 DIABETES MELLITUS CONFERRED BY HLA CLASS II GENES. Irina Durbală
ASSESSMENT OF THE RISK FOR TYPE 1 DIABETES MELLITUS CONFERRED BY HLA CLASS II GENES Summary Irina Durbală CELL AND MOLECULAR BIOLOGY DEPARTMENT FACULTY OF MEDICINE, OVIDIUS UNIVERSITY CONSTANŢA Class II
More informationAssociation of HLA-DQ Genotype in Autoantibody-Negative and Rapid-Onset Type 1 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Association of HLA-DQ Genotype in Autoantibody-Negative and Rapid-Onset Type 1 Diabetes SHOICHIRO TANAKA, MD 1,2 TETSURO KOBAYASHI, MD 1 KOJI
More informationantigen Y. Kajita, D. Morgan, A.B. Parkes and B. Rees Smith
Volume 87, number 2 FEBS 2756 August 985 Labelling and immunoprecipitation antigen of thyroid microsomal Y. Kajita, D. Morgan, A.B. Parkes and B. Rees Smith Endocrine Immunology Unit, 7th Floor Medicine.
More informationPrevalence of LADA and frequency of GAD antibodies in diabetic patients with end-stage renal disease and dialysis treatment in Austria
Nephrol Dial Transplant (2005) 20: 559 565 doi:10.1093/ndt/gfh662 Advance Access publication 25 January 2005 Original Article Prevalence of LADA and frequency of GAD antibodies in diabetic patients with
More information